Overview

National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial

Status:
NOT_YET_RECRUITING

Trial end date:
2031-12-01

Target enrollment:

Participant gender:

Summary

Liver disease deaths are rising, but transplants remain scarce in India. With over 100,000 needed annually and only \~2,500 performed, non-transplant options are urgently needed. Regenerative therapy, especially mesenchymal stem cells (MSCs), shows promise but lacks validation, particularly for non-viral ACLF. The proposed NC-CHRM aims to develop and validate MSC-based therapy to promote native liver regeneration and offer a safe, effective, transplant-free treatment.

Phase:

PHASE3

Details

Lead Sponsor:

Institute of Liver and Biliary Sciences, India

Collaborator:

Indian Council of Medical Research

Treatments:

Steroids